CLINICAL RESEARCH
The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials
1
Department of Pharmaceutics and Pharmacy Practice, University of Karachi, Karachi, Pakistan
2
Department of Gastroenterology, Jamal Noor Hospital, Jamal, Pakistan
3
Department of Pharmacy Practice, Jinnah Sindh Medical University, Karachi, Pakistan
Submission date: 2023-07-27
Acceptance date: 2023-08-24
Publication date: 2023-09-30
Arch Med Sci Civil Dis 2023;8(1):31-37
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The challenge of eradicating Helicobacter pylori through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment.
Material and methods:
A total of 162 patients who were examined positive for H. pylori were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days.
Results:
The eradication rate of H. pylori in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group.
Conclusions:
Moxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for H. pylori infection in Pakistan.
The challenge of eradicating Helicobacter pylori through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment.
Material and methods:
A total of 162 patients who were examined positive for H. pylori were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days.
Results:
The eradication rate of H. pylori in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group.
Conclusions:
Moxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for H. pylori infection in Pakistan.
REFERENCES (26)
1.
Shah SRH, Almugadam BS, Hussain A, et al. Epidemiology and risk factors of Helicobacter pylori infection in Timergara city of Pakistan: a cross-sectional study. Clin Epidemiol Global Health 2021. 12: 100909.
2.
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
3.
Faisal N, Ul Haq MM, Shaikh H, et al. Helicobacter pylori infection; dyspeptic patients undergoing endoscopy: a hospital-based study. Prof Med J 2012; 19: 02, DOI: https://doi.org/10.29309/TPMJ/... .
4.
Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021; 22: 729-41.
5.
Shrestha AB, Pokharel P, Sapkota UH, et al. Drug resistance patterns of commonly used antibiotics for the treatment of Helicobacter pylori infection among South Asian countries: a systematic review and meta-analysis. Trop Med Infect Dis 2023; 8: 172.
6.
Rakici H, Ayaz T, Akdogan RA, Bedir R. Comparison of levofloxacin-and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. Digestion 2014; 90 261-4.
7.
Bago J, Pevec B, Tomic M, et al. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009; 121: 47-52.
8.
Hwang JJ, Lee DH, Yoon H, et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21: 10234-41.
9.
ICH Harmonised Tripartite Guideline: Guideline for good clinical practice. J Postgrad Med 2001; 47: 199-203.
10.
General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 2014; 81: 14-8.
11.
Fathima A, Sultana A. Clinical efficacy of a Unani formulation ‘Safoof Habis’ in menorrhagia: a randomized controlled trial. Eur J Integr Med 2012; 4: e315-22.
12.
Hwang JJ, Lee DH, Lee AR, et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015; 21: 5032-8.
13.
Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis 2015; 47: 108-13.
14.
Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45: 520-9.
15.
Akpinar MY, Aksoy EK, Sapmaz F, et al. Comparison of moxifloxacin-based therapies and standard bismuth-based quadruple therapy for first-line treatment of Helicobacter pylori infection. Arch Med Sci Civil Dis 2018; 3: 81-6.
16.
Siddiqui TR, Ahmed W, Arif A, et al. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. J Pak Med Assoc 2016; 66: 710-6.
17.
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022; 71: 1724-62.
18.
Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: is the end coming? World J Gastrointest Pharmacol Ther 2015; 6: 183-98.
19.
Hwang JJ, Lee DH, Lee AR, et al. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21: 5568-74.
20.
Ahmed MH, Abd-Elsalam S, Mahrous AM. Moxifloxacin based triple therapy as alternative to standard therapy in Helicobacter pylori eradication. Antiinfect Agents 2021; 19: 299-302.
21.
Hassan AM, Eid K, Eliwa K, et al. Two nitazoxanide-based quadruple regimens for eradication of Helicobacter pylori infection: a single-center randomized controlled trial. Al-Azhar Assiut Med J 2022; 20: 67-71.
22.
Keikha M, Askari P, Ghazvini K, Karbalaei M. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. J Global Antimicrob Resist 2022; 29: 420-9.
23.
Alhalabi M, Alassi MW, Eddin KA, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for Helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infect Dis 2021; 21: 642.
24.
Keikha M, Karbalaei M. Correlation between the geographical origin of Helicobacter pylori homB-positive strains and their clinical outcomes: a systematic review and meta-analysis. BMC Gastroenterol 2021; 21: 181.
25.
Demirci H, Ilikhan SU, Ozturk K, et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. Turk J Gastroenterol 2015; 26: 456-60.
26.
Kang KK, lee DH, oh DH, et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20: 6932-8.
Share
RELATED ARTICLE
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
